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Introduction
Wild-type or recombinant viruses used as vaccines and
human gene therapy vectors are an important develop-
ment tool in modern medicine. Some have demonstrated
high potential such as lentivirus, paramyxovirus and
adeno-associated-virus (AAV). These vectors are pro-
duced in adherent and suspension cell cultures (e.g.
HEK293T, A549, VERO, PER.C6, Sf9) using either transi-
ent transfection (e.g PEI, calcium phosphate precipita-
tion) or infection (e.g. modified or recombinant viruses)
strategies. Most of these processes are currently achieved
in static mode on 2-D systems (Roller Bottles, Cell Fac-
tories, etc.) or on suspended microcarriers (porous or
non-porous). However, these two systems are time-
consuming (large numbers of manipulation, preparation
of equipment, etc.) and hardly scalable. In regards to pro-
cess simplification and traceability, Integrity® iCELLis®
bioreactors offer a new solution for scalability and moni-
toring of adherent cell cultures.
The Integrity iCELLis Bioreactor
Integrity® iCELLis® bioreactors from ATMI LifeSciences
were designed for adherent cell culture applications
such as recombinant protein, viral vaccine and gene
therapy vector production. Using PET carriers trapped
into a fixed-bed, cells grow in a 3-D environment with
temperature, pH and dissolved oxygen controls. The
iCELLis technology can be used at small-scale (the
iCELLis nano from 0.5 to 4 m2) and manufacturing
scale (iCELLis 500 from from 66 to 500 m2) which eases
process scale-up and its overall utilization.
Materials and methods
All the experiments described here have been performed
in the bench-scale and pilot scale iCELLis bioreactors
containing iPack carriers made of 100% pure non-woven
PET fibers. Crystal violet was used for cell nuclei counts
from carriers.
Recombinant viral vectors production
Some recombinant entities are produced in the iCELLis
bioreactors using hybrid vectors. For example, A549-
stable packaging cell line, maintained in Optipro med-
ium + 1% FBS, can deliver recombinant AAV vectors
frequently used in gene transfer applications (Inserm
UMR 649, Institut de Recherche Thérapeutique).
Alternatively, other rAAV vectors are obtained by tran-
sient transfection. In this case, HEK293-T cells are regu-
larly found to be sensitive to the viral DNA and
transfection reagent complex (generally polyethylenimine
- PEI or phosphate calcium precipitate). The transfer of
the transfection process from static or dynamic systems
to the iCELLis bioreactors requires some adaptation in
order to fully benefit of both technologies. Using a fluor-
escent protein marker, the transfected cells can be
observed during the culture and the viral vectors can be
quantified after the harvest.
Transfection method using the PEI/DNA complexes is
frequently found in cell suspension processes due to its
high efficiency and adaptability to high-throughput sys-
tems. The circulation pattern of the medium through the
fixed-bed of the iCELLis system allows a good contact
between cells and transfection complexes.
The transfection by phosphate precipitation is a static
method where the DNA precipitates settle on the cells.
For this reason, it is difficult to apply this technic in
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iCELLis bioreactor, the agitation speed has to be minimal
to get a medium circulation through the fixed-bed. This
maintains the precipitate in suspension while giving the
longest contact time between these precipitates and the
cells. The iCELLis system with its pH regulation and
low-shear circulation is well adapted for this method sen-
sitive to small pH changes and reagent mix.
Results
Recombinant adeno-associated virus vector production
Recombinant AAV vectors were produced in an A549
based stable packaging cell line containing the AAV2 rep
and cap genes from various AAV serotypes. Using a dual
adenovirus infection (wild-type Ad5 followed by hybrid
Ad/AAV) in the iCELLis nano bioreactor under perfusion
mode, recombinant particles were harvested up to
96 hours post-infection. The expression levels of the
AAV2 rep and cap genes from various AAV serotypes
were assessed by western-blot and qPCR. This 8-days pro-
cess demonstrated higher vector particles production in
the iCELLis bioreactor compared to CS-5 control (4.5 ×
108 vs 3.1 × 108 vg/cm2, 72 h after the first infection)
(Inserm UMR649, Institut de Recherche Thérapeutique).
Triple transient transfection using PEI was performed
in the iCELLis nano system (0.53 m2, 40 mL fixed-bed)
for the production of serotype 5 AAV in HEK 293T cells.
Cells were seeded at 80,000 cells/cm2 in the CS10 and
the iCELLis bioreactor. Twenty-four hours post-inocula-
tion, the DNA-PEI mix containing the GFP gene was
added to fresh medium inside the bioreactor. Cells were
still growing on the carriers after the transfection. The
expression of GFP by cells demonstrated that the trans-
fection had a high efficiency rate in both vessels (FACS
analysis on sampled carriers for the iCELLis bioreactor).
Green Fluorescent Units (GFU) and Viral Genome (VG)
were measured for the CS10 control and the iCELLis
nano bioreactor. Viral particles were harvested using a
freeze/thaw method, suboptimal in the case of the iCEL-
Lis system. The GFU and VG titers/cm2 in the iCELLis
bioreactor were about 53% of the control (Figure 1)
(Dept of Biochemical Eng. - UCL).
Conclusions
We demonstrated that the iCELLis system could be very
useful for production of viral vaccine and gene therapy
vectors. The iCELLis platform facilitates handling and
scale-up, high biomass amplification and sterile contain-
ment within a closed system. Moreover, in many cases,
the specific culture environment enhances virus produc-
tion yields.
Specifically, after some optimization of the culture
parameters, it was demonstrated that rAAV vectors
were produced by modified A549 cells in high viral level
in the 0.53 m2 iCELLis bioreactor. The maximum viral
yield achieved in the bioreactor was 4.5 × 108 vg/cm2,
which was higher than the yield per cm2 obtained in a
CellSTACK vessel (3.1 × 108 vg/cm2).
Finally, the preliminary results of transfection demon-
strated that the method using PEI is applicable in the
iCELLis bioreactors, with optimization of the viral
recovery at harvest yet to be performed. This also
demonstrated that the iCELLis can be considered as a
solution for transient transfection processes at large
scales.
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Figure 1 Comparison of Green Fluorescent Units and Viral
Genome/cm2 and VG/GFYU ratio in the CS10 and iCELLis nano
0.53 m2.
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